Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Total Liabilities (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Total Liabilities for 3 consecutive years, with $140.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Liabilities rose 218.95% to $140.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $140.6 million, a 218.95% increase, with the full-year FY2024 number at $47.2 million, down 82.15% from a year prior.
  • Total Liabilities was $140.6 million for Q3 2025 at Inhibrx Biosciences, down from $143.6 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $264.4 million in Q4 2023 to a low of -$129.6 million in Q3 2023.
  • A 3-year average of $71.1 million and a median of $45.6 million in 2024 define the central range for Total Liabilities.
  • Peak YoY movement for Total Liabilities: tumbled 82.15% in 2024, then skyrocketed 1381.09% in 2025.
  • Inhibrx Biosciences' Total Liabilities stood at $264.4 million in 2023, then crashed by 82.15% to $47.2 million in 2024, then soared by 198.08% to $140.6 million in 2025.
  • Per Business Quant, the three most recent readings for INBX's Total Liabilities are $140.6 million (Q3 2025), $143.6 million (Q2 2025), and $148.2 million (Q1 2025).